Eur J Neurol. 2022 Jul 15. doi: 10.1111/ene.15496. Online ahead of print.
ABSTRACT
AIMS: To explore associations between plasma neurofilament light chain concentration (pNfL; pg/mL) and disease activity in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and examine the usefulness of pNfL concentrations in determining disease remission.
METHODS: We examined pNfL concentrations in treatment-naïve CIDP patients (n=10) before and after intravenous immunoglobulin (IVIg) induction treatment, differences in pNfL concentrations in patients on maintenance IVIg treatment who had stable (n=15) or unstable disease (n=9), and in clinically stable IVIg-treated patients (n=10) in whom we suspended IVIg to determine disease activity and ongoing need for maintenance IVIg. pNfL concentrations in an age-matched healthy control group were measured for comparison.
RESULTS: Treatment-naïve patients: pNfL concentration was higher in patients before IVIg treatment than healthy controls and subsequently reduced comparable to control group values after IVIg induction. CIDP patients on IVIg treatment: pNfL concentration was significantly higher in unstable patients than stable patients. A pNFL concentration above 16.6 pg/mL identified unstable treated CIDP from stable treated CIDP (sensitivity= 86.7%, specificity= 66.7%, area under ROC= 0.73). Treatment withdrawal group: There was statistically significant correlation between pNfL concentration at time of IVIg withdrawal and the likelihood of relapse (r=0.72, p<0.05), suggesting an association of higher pNfL concentration with active disease.
CONCLUSION: pNfL concentrations may be a sensitive, clinically useful biomarker in assessing subclinical disease activity.
PMID:35837802 | DOI:10.1111/ene.15496